Bone tissue is continually being remodelled according to physiological circumstances. Two main cell populations (osteoblasts and osteoclasts) are involved in this process, and cellular activities (including cell differentiation) are modulated by hormones, cytokines and growth factors. Within the last 20 years, many factors involved in bone tissue metabolism have been found to be closely related to the inflammatory process. More recently, a cytokine family sharing a common signal transducer (gp130) had been identified, which appears to be a key factor in bone remodelling. This family includes interleukin 6, interleukin 11, oncostatin M, leukaemia inhibitory factor, ciliary neurotrophic factor and cardiotrophin-1. This paper provides an exhaustive review of recent knowledge on the involvement of gp130 cytokine family in bone cell (osteoblast, osteoclast, etc.) differentiation/activation and in osteoarticular pathologies.
These cells, which have an extensive endoplasmic reticulum and numerous free ribosomes in the cytoplasm, are connected by gap junctions. Secondary cell types such as monocytes/macrophages and endothelial cells also contribute to the bone remodelling by direct contact with osteogenic cells or by the release of soluble factors (cytokines, growth factors). In 1969, Frost showed that osteoblasts and osteoclasts are closely associated in time and space. 1 Thus, after receiving a bone stimulus (i.e. mechanical load, hormones, growth factors) from the lining, osteoblastic and osteoclastic cells appear on the bone surface and resorb the mineral components of bone by an acid extracellular mechanism. [2] [3] [4] Osteoblastic cells stimulated by osteoclastic contacts and/or osteoclastic soluble factors deposit osteoid on the resorption site, initiating bone formation. 5 Osteoblasts not only initiate but also control bone mineralization.
Although all osteogenic cells (osteoblasts, osteoclasts) contribute individually to bone remodelling, their cellular interactions control cellular activities and the intensity of bone remodelling. These interactions can be established through cell-cell contact, 6 which may involved molecules from the integrin family 7 or the release of many polypeptidic factors and/or their soluble receptor chains. [8] [9] [10] These factors can act directly on osteogenic cells on their precursors and control differentiation, formation and functions (matrix formation, mineralization, resorption, etc.). Among the known soluble polypeptide factors, a pleiotropic cytokine family sharing a common signal transducer (gp130) 11 plays a key role during bone remodelling. This family includes cardiotrophin-1, CNTF, IL-6, IL-11, LIF and OSM, which all show structural similarities (amino acid sequence, threedimensional structure) and produce similar activities on a variety of target cells, including haematopoietic cells, hepatocytes, neurons, embryonic stem cells and bone cells. [12] [13] [14] [15] [16] [17] [18] [19] [20] This review will focus on the involvement of gp130 cytokine family (cardiotrophin-1, CNTF, IL-6, IL-11, LIF, OSM) on the formation and functions of osteogenic cells (osteoblasts, osteoclasts). An overview will be provided of the potential implication of these cytokines during osteoarticular pathologies. LIF and OSM are clearly related cytokines whose genes are located on chromosome 22q12 distal to the Ewing's sarcoma break-point and within 500 kb of each other. 21 Moreover, OSM can mimic LIF activities both in vitro and in vivo and shares common gp130 and gp190 transducing receptor subunits with LIF, accounting in part for their redundancy. [21] [22] [23] [24] [25] LIF is produced by numerous cell types, including lymphocytes, 26 monocytes, 27 bone-marrow stromal [28] [29] [30] and osteoblastic cells. 31, 32 Malignant cells also express LIF cytokine.
Leukaemia inhibitory factor (LIF), oncostatin M (OSM) and bone cells
33,34 LIF produced by osteogenic cells and mesenchymal cells is regulated by key molecules involved in bone metabolism, such as PTH and PTHrP. 31 Moreover, Pollock et al. have shown that both LIF and IL-6 are physiologically important mediators of at least some actions of PTH and PTHrP. 31,35 OSM production is generally restricted to haemopoietic cells, and no production by osteogenic cells has yet been detected.
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The first evidence of LIF activities during bone remodelling steps was provided by Metcalf and Gearing, who showed that mice engrafted with LIFcDNA transfected cells producing high amounts of LIF developed a fatal syndrome within 12-70 days characterized by cachexia, excessive new bone formation and ectopic calcifications in skeletal muscles and heart. 39, 40 The effect of LIF and OSM on bone remodelling may be mediated by osteoblasts and bone-marrow stromal cells which, unlike osteoclasts, express receptors for both.
24,41-43 However, the activity of LIF and the presence of LIF receptor chain (gp190) have recently demonstrated in osteoclast-like cells cultured from human giant-cell tumour of bone.
44, 45 Nonetheless, LIF and OSM stimulated osteoclast-like cell formation and resulting resorption mechanisms when bone-marrow cells were co-cultured in vitro in the presence of osteoblasts. 46 Their receptors are active on osteoblastic cells and transduce the signal via protein phosphorylations (tyrosine kinase [47] [48] [49] [50] [51] and non-tyrosine kinase 52 pathways). At the present time, osteoblasts appear to be the main target of LIF and OSM and could act indirectly on osteoclasts via the release of prostaglandins. [53] [54] [55] IL6-type cytokines (LIF, OSM, IL-6) that utilize the gp130 signal transducer are potent anti-apoptotic agents on osteoblastic cell types (MC3T3- . 56 Thus, these cytokines like TGF-are able to counteract the effect of serum starvation or TNF. The induction of apoptosis in human MG-63 cells is associated with an increase in the ratio of the pro-apoptotic protein bax to the anti-apoptotic protein bcl-2, whereas oncostatin M prevents this change. LIF and OSM also influence the differentiation/proliferation system of osteoblasts. The effects of LIF on the proliferation of osteoblastic cells are reported to have a stimulatory or inhibitory effect (depending on the model used, on the age of the animals and the site). [57] [58] [59] [60] [61] [62] [63] If LIF and OSM can modulate the differentiation/proliferation system, they can also influence the physicochemical characteristics of the bone mineral formed (i.e. ionic microenvironment, etc.). Such variations have been observed in a murine heterotopic calcification model, 64 where LIF and OSM increased the number of bone-marrow stromal cell progenitors with osteogenic potential. 65 In this model, both cytokines induced an immature state of the mineral deposited on the extracellular matrix, as revealed by the presence of environment rich in labile non-apatitic phosphate, carbonate and HPO 4 . 66 Similar results have been obtained in in vitro rat bone-marrow stromal cell cultures. 67 The effect of LIF and OSM on osteoclastic activation and resorption are not so clear. Thus, Turner et al. analysed the effects of injected LIF in growing rats and have observed that high systemic concentrations of LIF resulted in hypercalcaemia with no changes in bone turnover. 68 LIF and OSM increased the amounts of mineral deposited in these various models, but also modified the quality of the mineral, which is one of the key parameters regulating the resorption mechanism induced by osteoclasts. 69 Although both cytokines can influence mineral phases and osteoclast activities, no direct action on these cells has yet been demonstrated, essentially because of the difficulties in obtaining a pure population of osteoclasts. However, numerous data have reinforced the potential role of both cytokines in resorption mechanisms. [43] [44] [45] [46] [70] [71] [72] For example, in vitro exposure of human long-term bone-marrow culture to recombinant human LIF and OSM significantly increased the number of multinucleated cells formed after three weeks of culture. 73, 74 The multinucleated cells formed expressed the macrophage polykaryon phenotype and were capable of low-grade resorption in the presence of bone-marrow stromal cells. OSM reduced the resorption induced by these cells. OSM and LIF could thus modulate bone remodelling toward such mechanisms (orientation of bone-marrow mononuclear cell differentiation to macrophage polykaryon phenotype). These results are in agreement with those obtained by Sarma and Flanagan, who showed that LIF did not increase bone resorption but upmodulated 23c6-positive cells (an antibody that recognizes the vitronectin receptor, which is one of the characteristics of osteoclasts) in a human bone-marrow mononuclear cell fraction co-cultured with human bone-marrow stromal cells. 75 Moreover, Benahmed et al. found that LIF inhibits the differentiation of monocytes into macrophages and their ability to manifest macrophagic activity. 76 Similarly, Sabokbar et al. have shown that LIF, like IL-4, inhibits the osteoclastic differentiation (tartrate-resistant acid phosphatase activity and lacunar bone resorption) from monocyte co-cultured with osteoblast-like cells in presence of polymethylmethacrylate wear particules. 77 Numerous proteinases produced by bone cells (osteoblasts, osteoclasts) contribute to bone remodelling. Thus, the prevention of bone resorption by collagenase and/or gelatinase inhibitors or by cysteine inactivators has provided direct evidence for the participation of cysteine proteinases and matrix metalloproteinases in bone resorption. Varghese et al. 78, 79 have demonstrated that LIF and OSM stimulates collagenase-3 (MMP-13) and tissue inhibitors of metalloproteinase-1 (TIMPs) expression in osteoblasts, but do not regulate the expression of gelatinase A (MMP-2), B (MMP-9), TIMP-2 and TIMP-3 in primary cultures of osteoblast-enriched cells isolated from fetal rat calvaria. 80 These results are in agreement with those obtained by Damiens et al. (personal communication) in osteoblastic type cells such as SaOS2 or MG-63, 81 and those of Cowell et al. who showed that OSM upmodulated collagenase-3 expression in chondrosarcoma cells. 82 Various transgenic or knockout mice have been developed to determine the real involvement of LIF and OSM in bone remodelling. [83] [84] [85] [86] [87] [88] Bone metabolic evidence is suggested by data obtained from chronic overproduction of LIF following the introduction of LIF transgenes.
39,40 Shen et al. generated a transgenic mouse line that expressed diffusible LIF protein in T cells. 83 No abnormalities in bone growth appear to have been detected in this study. However, the limited overproduction of LIF protein by T cells made the evaluation of LIF effects difficult. Escary et al. 84 as well as Stewart et al. 85 have developed LIF-deficient mice derived by gene-targeting techniques. Their model indicates that transient expression of LIF in mice is essential for blastocyte implantation and maintenance of haematopoietic stem cells and thymocyte stimulation. They also observed that viable homozygous mice deficient in LIF expression had a retarded postnatal growth rate (body weight 25-35% smaller). However, no specific analysis of bone tissue was performed in their studies. In transgenic mice overexpressing OSM, Malik et al. observed that the animals developed osteopetrotic bone tissue, possibly by stimulation of bone formation and inhibition of bone resorption. 84 As the effects of both cytokines can be redundant with those of IL-6, IL-11, CT-1 and CNTF, gp130 gene knockout mice and gp190 gene knockout mice have been generated. 87, 88 Kawasaki et al. compared bone tissue from gp130-deficient and wild-type newborn mice 87 and observed a decrease in trabeculae at the metaphysical region in tibia and radii of deficient mice as well as an increase in the number of osteoclasts. No apparent differences were noted in the distribution of alkaline-positive osteoblasts and the osteoid surface on trabecular bone of the metaphysical region, whereas the volume of mineralized trabecular bones was decreased at mandibulae. These data confirm the role of gp130 cytokine family during bone remodelling, but also indicate that osteoclast formation is not solely dependent on gp130 signalling. These cytokines could have an inhibitory effect on osteoclastic formation, and the persistence of osteoclasts in gp130-deficient mice may be caused by the functional redundancy of bone-resorbing factors. Similarly, experiments performed with gp190-deficient mice 88 showed that this defect induced a reduction of fetal bone volume. The decrease of osteoid volume associated with an increase of osteoclast number resulted in osteopenia of perinatal bone. These results confirm those obtained in gp130-deficient mice.
INTERLEUKIN 6 (IL-6), INTERLEUKIN 11 (IL-11) AND BONE CELL
IL-6 and IL-11, like LIF, OSM, CT-1, and CNTF, are multifunctional cytokines [16] [17] [18] [19] 89 which share the common receptor transducer gp130. 11, 20, 48, 90 A large number of cell types express IL-6 such as monocytes, fibroblasts, endothelial cells, chondrocytes, bonemarrow stromal cells, keratinocytes and bone cells. 91 These large production sites correspond to numerous biological activities, such as functions in immune cells, haematopoiesis, acute phase response during inflammation, the neurological system and bone remodelling (see references 92, 93 104 IL-11 was originally discovered as a crossreacting cytokine in an IL-6 bioassay. 105 IL-11 gene is expressed in a variety of normal and cancer cells of mesenchymal origin (bone-marrow stromal cells, lung, uterus, connective tissues, skin, testis, etc.) and is modulated by several inflammatory cytokines and agonists as well as hormones. 90 Primary human osteoblasts produce a very low amount of IL-11, which is strongly upmodulated by TGF-1.
106-108 IL-11 is also produced by bone-marrow stromal cells and modulated by osteotropic agents. Thus, its production is stimulated by IL-1, PTH, basic FGF, and inhibited by interferon-.
109-112 IL-11 act synergistically with other cytokines (IL-3, IL-4, IL-13, stem cell factor, etc.) to stimulate various haemopoietic stages and lineages. Thus, IL-11 stimulates the proliferation of primitive stem cells. The other main activities concern its effects on epithelial cells (inhibition of proliferation), neurogenesis (stimulation of the proliferation of hippocampal neuronal cells), inflammation (stimulation of acute phase reactants; see reference 90 ). These results indicate that appropriate osteoblastic cells and bone-marrow stromal cells are potent producers of IL-6 and IL-11, which may be important components of the cytokine network mediating bone cell communications during bone remodelling.
Although osteoblastic cells express IL-6 mRNA and produce the protein, they apparently do not respond to this factor. 113, 114 Few data have concerned the effects of IL-6 on osteoblastic cells. ''High'' concentrations of IL-6 (>10 ng/ml) were found to produce a slight increase in tritiated thymidine in the UMR-106-01 tumour cell line. 115 Like LIF and OSM, IL-6 is a potent anti-apoptotic agent on osteoblastic cells via transcriptional activation of the p21 gene. 56, 116 Moreover, IL-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. 117 However, Hughes et al. have shown that IL-6 inhibits bone formation 118 in vitro, which suggests that studies on the quality of the mineral phases formed in presence of IL-6 could be crucial in determining the real impact of this cytokine on bone formation. The main activity of IL-6 on bone is its effect on osteoclastogenesis and bone resorption. Thus, Kuhihara et al. showed that IL-6 stimulates osteoclastlike formation in long-term human marrow culture by IL-1 release, whereas the addition of anti-IL-1 inhibits the increase in osteoclast formation induced by IL-6.
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IL-6 also mediates the same stimulatory effects as TNF 120 and PTH. 121 These data, which have been confirmed in vivo 122 and depend on the model used.
123
IL-6 also enhances PTHrp-mediated hypercalcaemia and bone resorption, by increasing the pool of osteoclastic progenitors and then after differentiation of mature osteoclasts.
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In a murine model, IL-6 strongly increases the formation of multinucleated cells only in the presence of IL-6 soluble receptor gp130. 47 Flanagan et al. demonstrated, using a model of human bone-marrow stromal cells recharged with non-adherent bonemarrow cells, that IL-6 failed to induce a similar stimulatory effect. 125 In this study, IL-6 was not able to replace the stromal factor(s) required for the formation of cells capable of resorbing bone. These authors concluded that IL-6 is not critical in stimulating osteoclastic bone resorption. IL-6 and LIF similarly had no effect in a murine model. 126 This discrepancy can be explained by the fact that the exact nature of these cells, referred to by some authors as ''osteoclast-like'', remains controversial (osteoclasts or macrophagepolykaryons?). 10 Curiously, IL-6 produced by osteoblasts in response to CD34 + haematopoietic bone-marrow cells 127 which are able to differentiate in osteoclasts under specific conditions. 128 In this case, what is the real involvement of IL-6 in the dichotomic system: osteoclast and haematopoietic differentiation? The effect of IL-6 on osteoclasts in human bone marrow has been analysed recently by stromal cells transfected by a cDNA coding for human IL-6 and injected into human bone implants implanted in NOD/ SCID mice. 129 These data demonstrate that only implants engrafted with IL-6/stromal cells had an upmodulation in osteoclast-lined mineralized trabecular bone surface. Similarly, in the human giant-cell tumour model, IL-6 antisense deoxyoligonucleotides inhibit bone resorption by these osteoclast-like cells. 130 IL-6 produced by these tumours may then be involved in the autocrine induction of osteolysis, which is associated with biologic aggressiveness. 131 IL-6 exerts its activities via a cell-surface receptor which consists of two glycoproteins, gp80 and gp130. When gp80 is occupied by IL-6, this complex binds to gp130 and transduces IL-6 signals. In this context, various studies have analysed the expression of these receptors to determine the target cells of IL-6 during osteoclastic differentiation/activation. 132, 133 Thus, Udagawa et al. have demonstrated that induction of osteoclast differentiation by IL-6 is dependent on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. 132 Tamura et al. showed that neither recombinant IL-6 nor soluble IL-6 receptor (gp80) induced osteoclast-like formation from mouse bonemarrow cells. Conversely, addition of IL-6 and IL-6-soluble receptor induced osteoclast-like formation. 46 However, these apparently contradictory results were mainly due to the differentiation level of bone tissue used and to methodological differences. More recently, Gao et al. showed that gp130 and IL-6 receptors are expressed on tartrate-resistant acid phosphatasepositive mononuclear cells and isolated murine osteoclasts. In this model, IL-6 caused enhancement of the resorbing activity in a dose-dependent manner, indicating the involvement of IL-6 in the formation and activation of osteoclasts. 132 The presence of IL-6 receptors on osteoclast membrane has been confirmed by confocal microscopy and by in situ reverse transcriptase PCR histochemistry. 133 Adebanjo et al. also found that IL-6, but not IL-11, reverses the inhibition of osteoclastic bone resorption induced by high extracellular Ca 2+ and may sustain osteoclastic activity versus an inhibitory Ca 2+ level generated locally during resorption. 134 The importance of the IL-6 function during bone remodelling has been confirmed in oestrogen-deficient animals. 135, 136 These studies indicate that ovariectomy does not induce any change in either bone mass or bone remodelling rates in the IL-6-deficient mice and that anti-IL-6 monoclonal antibodies inhibit upmodulation in osteoclast precursors occurring in oestrogen depleted mice. These results are in accordance with those obtained by Girasole et al. who demonstrated that ovariectomized animals display elevated serum levels of IL-6 that can be normalized by administration of oestradiol. 99 However, though serum IL-6 levels increase with age, no correlation was found between bone turnover, ovarian function and serum IL-6 level in a study of 80 normal women (24-87 years of age). 137 These results are not concordant with the study of Bismar et al. 138 who found increased IL-6 levels in patients with postmenopausal osteoporosis. At the present time, the actual involvement of IL-6 in patients with postmenopausal osteoporosis is still unclear. Moreover, macaques injected with recombinant IL-6 showed no upmodulation of calcium release, thereby indicating that there is no modulation of bone resorption in vivo. 139 Thus, there is still controversy about the candidate molecules that stimulate bone resorption during oestrogen depletion and subsequent osteoporosis. The protective effects of oestrogen for bone could involve two other candidates, namely TNF 140 and/or IL-11. 141 To complicate the various observations, Schiller et al. have observed that osteoclastogenesis induced by 1 , 25 (OH) 2 D 3 is partially dependent on IL-6 and is modulated by 17 -oestradiol through interference IL-6 receptor activation as well as inhibition of IL-6 produced by bone-marrow stromal cells. 100 IL-6 could also be an appropriate candidate during bone loss caused by androgen deficiency, 142 insofar as 17 -oestradiol and dihydroxytestosterone decrease the expression of gp130 and gp80 in the murine bonemarrow cells. 143 These studies have been supplemented by those of Nishida et al., who used a monoclonal antibody in normal and ovariectomized rats. 144 Osteoclast-like cells, as well as osteoblasts, express IL-11 receptor transcripts and a sequential relationship exists between expression of the calcitonin receptor mRNA and IL-11 receptor mRNA. 145 Gp130 signals, evoked by IL-11, are indispensable for IL-1-induced osteoclast formation. Further studies are required to elucidate the role of IL-11 in mature osteoclasts functional IL-11 receptors on osteoclasts (IL-11 does not influence by itself osteoclast survival and anti-gp130 antibody does not influence pit resorption by these cells). 145 However, IL-11 upmodulated the formation of osteoclast-like cells from mouse bone-marrow cells, 108, [145] [146] [147] as well as the surface of calcified matrix resorbed by these cells which involves both metalloproteinases and products of achidonic acid metabolism. 145, 147 IL-11 has been implicated in oestrogen deficiency-induced bone loss. Thus, a neutralizing monoclonal antibody inhibited the osteoclastogenesis induced by 1 , 25 (OH) 2 D 3 and PTH in both normal and ovariectomized mice (IL-6 antibody was an inhibitor only in ovariectomized mice). 108 Recent in vitro data also indicate that IL-11 production induced by PTH or IL-1 in human bone-marrow stromal cells was not modulated by 17 -oestradiol 109 and that injected recombinant IL-11 did not modify biochemical parameters of bone remodelling in adult ovariectomized rats. 148 Moreover, IL-6 and IL-11, like LIF and OSM, can induce bone resorption by modulating proteinase release by bone cells. 81, 147, 149 Transgenic or knockout mice have been developed to determine the real involvement of IL-6 in bone remodelling (Table 1) . Thus downmodulation in osteoblasts and in osteoid, as well as a decrease in osteoclasts and bone resorption, has been observed predominantly in transgenic mice overexpressing IL-6. These modulations resulted in the suppression of bone turnover. 150 Overexpression of IL-6 also induced plasmocytomas, indicating the potential involvement of this cytokine in myeloma pathology. 151, 152 The role of IL-6 during bone turnover was confirmed in IL-6-deficient mice which showed an increase of bone turnover and were protected from bone loss caused by oestrogen depletion. 136 Similar transgenic mice have been generated with IL-11, but no data are available concerning the quality of mouse bone, and bone turnover has not been studied.
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CARDIOTROPHIN-1 (CT-1) AND CILIARY NEUROTROPHIC FACTOR (CNTF) AND BONE CELLS
Although considerable data have been published concerning the role of CT-1 and CNTF, particularly in muscular and nervous systems, 13,14 no specific study has been performed concerning the effects of these cytokines on the bone system. Apparently, CNTF did not modify embryonic development and growth in CNTF gene knockout mice.
14
gp130 CYTOKINE FAMILY AND OSTEOARTICULAR PATHOLOGIES
The gp130 cytokine family is involved in osteoarticular pathologies, mainly in osteolytic diseases (giant-cell tumours, Paget's disease, bone metastasis) and in rheumatoid arthritis. Thus, because of its involvement in bone remodelling and its expression by some tumours cells, LIF has been studied in vivo in human primary benign and malignant tumours. 155 In this study, LIF was never detected in any sera tested, in control urine samples, or in supernatants from normal cancellous bone cultures. A high level of LIF was found in all supernatants from malignant tumour cultures (100%) and in supernatant from cultured benign tumours (86%). LIF levels were particularly high in supernatant from chondrosarcoma. Immunohistochemical analysis revealed that LIF is present in all benign endochondromas and malignant chondrosarcomas, but not in control tissue. 156 The cytokine is localized in cartilage cells, and the number of stained cells ranges from less than 5% in endochondroma of the hand to more than 70% in high-grade chondrosarcoma. These studies raise the question of the significance of LIF in tumour-associated bone resorption and the potential role of this cytokine as a prognostic marker. The role of LIF during malignant osteolysis has been confirmed by Gouin et al., who found the presence of LIF receptors on osteoclast-like cells from human giant-cell tumours. 44 Similarly, IL-6 could be involved during osteolysis induced by giant-cell tumours, as described by Reddy et al. 130 , 157 Interleukin 6 antisense deoxyoligonucleotides inhibited bone resorption by giant cells from human giant-cell tumours of bone, demonstrating the autocrine biological activity of IL-6 on osteoclasts. Several models inducing experimental bone metastasis 158 have been used to study the role of the gp130 cytokine family in the development of bone metastasis. Bone-marrow metastasis is usually the initial step in the formation of bone metastasis, and interaction between tumour cells and bone-marrow cells affects osteoclast formation in bone marrow. Thus IL-6, IL-11 and LIF have been suspected to participate in the formation of osteolytic bone metastasis. [159] [160] [161] [162] [163] [164] This is the case of A375 melanoma cell line, which formed multiple osteolytic lesions when cells were injected into the left ventricle of mice.
165 IL-6 and LIF produced by A375 cell lines may be involved in the differentiation and activation of osteoclasts in association with stromal cells during the development of bone metastasis. 166 IL-6 has been reported to be involved in bone destruction in malignant-hypercalcaemia. [159] [160] [161] Similarly IL-11 produced by endothelial cells and cancer cells may induce the formation of osteolytic bone metastasis. 162, 163 Akatsu et al. also found that the mouse mammary tumour cell line, MMT060562, released LIF, which in turn stimulated osteoclast formation via a stromal cell-dependent pathway. 164 IL-6 has been shown to play a key role in the generation of plasmocytomas 151, 152 , which has been confirmed by Bataille et al. 167, 168 and more recently by Nishimoto et al. 169 and Zhang et al. 170 whereas IL-6, like IL-11, LIF and OSM, induces proliferation in vitro of human plasmocytoma cells via their common signal transducer, gp130. IL-6 is then expressed by myeloma cells and mediates the autocrine growth of myeloma cells. 171 Moreover, Garrett et al. have shown that IL-6 produced by activated osteoclasts enhances myeloma growth in vivo. 172 The pathogenesis of bone lesions in multiple myeloma involves bone cells and bone-marrow stromal cells, 173,174 as well as various molecules such as cytokines or proteinases. 175 Raised serum OSM was related to higher serum IL-6, C-reactive protein levels and also 2microglobu-lin 176, 177 (which is considered to be the single most important prognostic factor in multiple myeloma). 178 Thus, OSM and IL-6 levels may be significant prognosis parameters. In Paget's disease of bone, the main abnormality concerns osteoclasts, which are increased in size and possess a large number of nuclei. 179 IL-6 and IL-6 receptors are strongly expressed by osteoclasts in patients with Paget's disease and may be involved in the differentiation/activation of osteoclasts during this pathology. 180 Rheumatoid arthritis is an autoimmune and systemic inflammatory disease of uncertain aetiology characterized by acute phase proteins in serum, chronic joint inflammation and severe cartilage alterations (until complete destruction). Numerous cytokines have been measured in the serum and/or synovial fluid of CT-1, CNTF) . [186] [187] [188] [189] [190] [191] The activity of these cytokines on cartilage metabolism is varied. LIF and OSM promote cartilage degradation in vitro 192, 193 and in vivo and have induced leukocyte infiltration in goat joints. 194, 195 All members of the gp130 cytokine family analysed (IL-6, IL-11, OSM, LIF, CNTF) suppressed proteoglycan synthesis in in vitro experiments. 193 During rheumatoid arthritis, some potential sources of the gp130 cytokine family are chondrocytes, synoviocytes and leukocytes infiltrating joints (a correlation has been found between LIF expression in synovial fluid and leukocyte count 186 ). 191, [196] [197] [198] [199] [200] The destruction of cartilage in rheumatoid arthritis may be also controlled by the release of proteases and their inhibitors, which degrade various components of the extracellular matrix. Thus, the gp130 cytokine family can influence cartilage degradation by modulating these protease activities. [201] [202] [203] [204] [205] Despite the numerous studies published on this subject, the role of the gp130 cytokine family in the regulation of cartilage macromolecule metabolism is still uncertain. 206 Histologic analysis has revealed peri-articular trabecular bone resorption in patients with rheumatoid arthritis. 207 Takayanagi et al. and Fujikawa et al. have described a new mechanism of bone destruction in rheumatoid arthritis in which synovial fibroblasts can support in vitro differentiation of monocytes/macrophages in osteoclasts. 208, 209 These locally produced factors could contribute at least partially to joint destruction through osteoclastogenesis.
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CONCLUDING COMMENTS
During the last decade, various soluble factors have been found to act on bone cells. However, it is difficult to establish a hierarchical order for these factors. Members of the gp130 cytokine family appear to play a key role in bone remodelling events by acting on both osteoclasts and osteoblasts. The fact that these factors are detected during osteoarticular pathologies is indicative of their importance. Nevertheless, their exact role (bone apposition, bone resorption) in bone cells remains an open question. Although cytokines, growth factors and hormones are the main protagonists of bone remodelling, phylogeny can provide further clues to this phenomenon. 212 Thus, it has been shown that the osteoclast appeared during the evolutionary transition of bony fishes from salt to fresh water where calcium homeostasis could no longer be regulated by transport across epithelia in contact with salt water. Therefore, bone represents a stock of calcium ions that regulate cellular activity, which in turn influences calcium release from bone. Calcium would thus appear to be one of the primary parameters of bone remodelling, acting before cytokines, growth factors and hormones. 
